Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutanous Allergen Administration
NCT ID: NCT00457444
Last Updated: 2007-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
35 participants
INTERVENTIONAL
2005-12-31
2006-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Secondary Objectives Comparison of the efficacy of the placebo with that of the epicutanous pollen allergen administration evaluated by visual analog symptom scales (nasal itching, sneezing, rhinorrhea, conjunctival redness, and lacrimation, lung symptoms ), Comparison of the inhibition of the allergic response assessed by skin prick test after epicutanous pollen allergen administration and placebo epicutaneous administration.
* Trial with medicinal product
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pollen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of grass pollen allergic rhinitis
* Male and female between 18 years to 65 years
* Positive skin prick test to grass pollen
* Positive nasal provocation test
Exclusion Criteria
* Perennial allergic rhinitis
* Symptoms of infectious disease with rhinitis in between the last 2 weeks
* Surgical intervention in between the last 30 days
* Pregnancy or nursing
* History of HIV or AIDS
* Mastocytosis (cutaneous or systemic)
* Significant cardiovascular disease
* Hypertension (blood pressure \> 160 / 95)
* Significant pulmonary, renal and/or hepatic disease
* Significant hematological disorder
* Moderate or severe asthma
* History of malignancy
* History of neurological or psychatric disease
* Autoimmune disease
* Antihistamines with longed half-lives in the last week
* Systemic or topical steroids for 5 days
* Active infectious disease
* Contraindicated medications: - immunosuppressive agents
* Betablockers
* ACE-inhibitors
* Tricyclic antidepressants
* Daily use of Beta-agonists or steroid inhalers
* Participation in another clinical trial /study in between the last 60 days
* Participation in another clinical trial / study at the moment
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zurich
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Studienregister MasterAdmins
Role: STUDY_DIRECTOR
UniversitaetsSpital Zuerich
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Zurich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZU-SkinSIT-001
Identifier Type: -
Identifier Source: org_study_id